A Phase 1 interventional study of NTLA-2001 in Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy and Wild-Type Transthyretin Cardiac Amyloidosis, sponsored by Intellia Therapeutics. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Intellia Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 15th largest by enrollment of the 23 interventional ones that give a count, is one of 6 that started in 2020, is one of 2 in phase 1, and was the 19th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in France, United States, Argentina and 21 more countries
Ages 18–75
Gérond'if · Sites in France
Ages 80+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10
First in 2007; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 128 across the 23 interventional studies, 175 across the 12 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 35 have an industry lead sponsor. The 10 most frequent:
Intellia Therapeutics is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Intellia Therapeutics has 3 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
5 of the studies in Amyloid Neuropathies, Familial with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05103943Centre Hospitalier Régional d'OrléansAmyloidosis TTR Flow Reserve Evaluation | 2026-12-11 |
| NCT04849754GCS Ramsay Santé pour l'Enseignement et la RechercheAnalysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy | 2026-12-31 |
| NCT04535349University Hospital, CaenQuantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis | 2027-06-15 |
| NCT05101304Saving Lives MattersRegistre HEAR, Healthcare European Amyloidosis Registry | 2027-06-30 |
| NCT06427304Gérond'ifCardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure | 2027-07-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt-CM)
For ATTRv-PN participants, Part 1 consists of an open-label, single-ascending dose study, which identifies the dose for evaluation in the cohort expansion of Part 2. Part 2 will follow as an open-label, dose expansion study to further characterize the activity of NTLA-2001, provide an initial assessment of the effect of NTLA-2001 on clinical measures of neuropathy and neurological function, and obtain additional safety data.
For ATTR-CM participants, Part 1 consists of an open-label, single-ascending dose study, which identifies the dose for evaluation in the cohort expansion of Part 2. Part 2 will follow as an open-label, dose expansion study to further characterize the activity of NTLA-2001, provide an initial assessment of the effect of NTLA-2001 on cardiac measures, and obtain additional safety data.
All participants who are dosed with NTLA-2001 will be offered to participate in a long-term safety monitoring follow-up study via a separate protocol.
Polyneuropathy Inclusion Criteria:
Polyneuropathy Exclusion Criteria:
Use of any of the following TTR-directed therapy for ATTR within certain timeframe:
Cardiomyopathy Inclusion Criteria (UK only):
Cardiomyopathy Exclusion Criteria (UK only):
Use of any of the following TTR-directed therapy for ATTR within certain timeframes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants, assigned to one of 4 dose-escalation cohorts, will receive a single dose of NTLA-2001.
Biological: NTLA-2001
Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.
Biological: NTLA-2001
Participants, assigned to one of 2 dose-escalation cohorts, will receive a single dose of NTLA-2001.
Biological: NTLA-2001
Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.
Biological: NTLA-2001
Participants assigned to the follow-on dosing cohort will receive a subsequent dose of NTLA-2001.
Biological: NTLA-2001
A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
Number of Participants with Treatment-Emergent Adverse Events
Time frame: up to Day 730
Number of Participants with Clinically Significant Clinical Laboratory Test Findings
Time frame: up to Day 730
Number of Participants with Clinically Significant Safety Measurements
Time frame: up to Day 730
Percent Change from Baseline in Serum TTR (enzyme-linked immunosorbent assay [ELISA])
Time frame: up to Day 730
Percent Change from Baseline in Serum Prealbumin
Time frame: up to Day 730
Mean Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Measurable Concentration (AUClast) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA
Time frame: up to Day 730
Mean Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA
Time frame: up to Day 730
Mean Maximum Concentration (Cmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA
Time frame: up to Day 730
Mean Time of the Maximum Concentration (Tmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA
Time frame: up to Day 730
Mean Terminal Half-Life (t½) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA
Time frame: up to Day 730
Mean Apparent Clearance (CL) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA
Time frame: up to Day 730
Mean Volume of Distribution (Vd) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA
Time frame: up to Day 730
Change from Baseline in Anti-Drug Antibody to NTLA-2001 and Anti-Cas9 Protein Antibody to Transgene Product Levels
Time frame: up to Day 730
Polyneuropathy only: Change from Baseline in Familial Amyloid Polyneuropathy (FAP) Stage.
Time frame: up to Day 730
Polyneuropathy only: Change from Baseline in Polyneuropathy Disability (PND) Score
Time frame: up to Day 730
Polyneuropathy only: Change from Baseline in Modified Body Mass Index (mBMI)
Time frame: up to Day 730
Polyneuropathy only: Change from Screening in Neuropathy Impairment Score (NIS)
Time frame: up to Day 730
Polyneuropathy only: Change from Baseline in Modified Neuropathy Impairment Score +7 (mNIS+7)
Time frame: up to Day 730
Polyneuropathy only: Change from Screening in 10-Meter Walk Test (10-MWT)
Time frame: up to Day 730
Polyneuropathy only: Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)
Time frame: up to Day 730
Polyneuropathy only: Change from Baseline in EuroQOL (EQ)-5D-5L
Time frame: up to Day 730
Cardiomyopathy only: Change from Baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP)
Time frame: up to Day 730
Cardiomyopathy only: Change from Baseline in hs Troponin T
Time frame: up to Day 730
Cardiomyopathy only: Change from Baseline in Magnetic resonance imaging (MRI)
Time frame: up to Day 730
Cardiomyopathy only: Change from Baseline in Echocardiogram
Time frame: up to Day 730
Cardiomyopathy only: Change from Baseline in Cardio-pulmonary exercise test
Time frame: up to Day 730
Cardiomyopathy only: Change from Baseline in 6-Minute Walk Test (6-MWT)
Time frame: up to Day 730
Cardiomyopathy only: Change from Baseline in New York Heart Association (NYHA) Classification
Time frame: up to Day 730
Cardiomyopathy only: Change from Baseline in Patient-reported outcomes (KCCQ)
Time frame: up to Day 730
Ran from Nov 2020 to primary completion in Sep 2025, 58 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NTLA-2001
Amyloid Neuropathies, Familial →
Intellia Therapeutics